- Home
- MGNX vs MGYR Comparison
MGNX vs MGYR Comparison
Compare MGNX & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MGYR
- Stock Information
- Founded
- MGNX 2000
- MGYR 1922
- Country
- MGNX United States
- MGYR United States
- Employees
- MGNX N/A
- MGYR N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MGYR Savings Institutions
- Sector
- MGNX Health Care
- MGYR Finance
- Exchange
- MGNX Nasdaq
- MGYR Nasdaq
- Market Cap
- MGNX 99.7M
- MGYR 112.5M
- IPO Year
- MGNX 2013
- MGYR 2006
- Fundamental
- Price
- MGNX $1.82
- MGYR $17.26
- Analyst Decision
- MGNX Hold
- MGYR
- Analyst Count
- MGNX 6
- MGYR 0
- Target Price
- MGNX $3.20
- MGYR N/A
- AVG Volume (30 Days)
- MGNX 630.9K
- MGYR 3.6K
- Earning Date
- MGNX 11-04-2025
- MGYR 10-30-2025
- Dividend Yield
- MGNX N/A
- MGYR 2.10%
- EPS Growth
- MGNX N/A
- MGYR 35.01
- EPS
- MGNX N/A
- MGYR 1.57
- Revenue
- MGNX $165,495,000.00
- MGYR $35,533,000.00
- Revenue This Year
- MGNX N/A
- MGYR N/A
- Revenue Next Year
- MGNX N/A
- MGYR N/A
- P/E Ratio
- MGNX N/A
- MGYR $10.93
- Revenue Growth
- MGNX 303.47
- MGYR 18.29
- 52 Week Low
- MGNX $0.99
- MGYR $12.10
- 52 Week High
- MGNX $5.10
- MGYR $19.04
- Technical
- Relative Strength Index (RSI)
- MGNX 51.87
- MGYR 50.91
- Support Level
- MGNX $1.69
- MGYR $17.05
- Resistance Level
- MGNX $1.83
- MGYR $17.27
- Average True Range (ATR)
- MGNX 0.10
- MGYR 0.15
- MACD
- MGNX 0.00
- MGYR -0.03
- Stochastic Oscillator
- MGNX 56.00
- MGYR 53.01
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About MGYR Magyar Bancorp Inc.
Magyar Bancorp Inc is a mid-tier stock holding company. The Company offers a full array of commercial and retail financial services, including the taking of time, savings and demand deposits; the making of commercial, consumer and home equity loans; and the provision of other financial services. The business consists of getting retail deposits from the general public in the areas surrounding the main office in New Brunswick, New Jersey and branch offices located in Middlesex and Somerset Counties, New Jersey, and investing those deposits, together with funds generated from operations and wholesale funding, in residential mortgage loans, home equity loans, home equity lines of credit, commercial real estate loans, commercial business loans, Small Business Administration loans.